Having just watched CEO Bresch wrap herself in the flag of motherhood while trying to justify the Shkreli-like increase on the epipen. This CEO and that strategy will likely have unfortunate consequences for Mylan sharelhoilders.
The interviewer did not press for details on how the price to the consumer of $100 has now become a $270 COST to distributors. Or how the market has been multiplied bu lobbying legislation for requirement of school eopipens. To be able to cover $300 of out-of-pocket costs when they collect $270 for it to begin with is illogical. They need to get the money from other channels, so its all just hooey. She blamed everybody else, congress, CVS, insurers, etc. 99% of the problem is Mylan. Seems she was almost making a case for single-payer, though not sure she meant to.
These facts will come out and she won't be able to so easily dismiss them. Mylan is on the fast track to being the new Turing. Call the PR dept.
While biotechs justifiably charge $100's thousands for new drugs that serve small patient pops, so they can cover required development and approval/trial costs, these kinds of mature-drug epi stories are what makes the case for the 'greed of wall street'.
The BoD overpaid themselves and the CEO, they breached their fiduciary responsibilities, they doctored their records and coerced and bought off their accuser...I want THE TRUTH!!!
AI
